Senior Consultant Ophthalmologist
Dr Kelvin Teo is a senior consultant ophthalmologist with over 15 years of experience caring for both adults and children with complex eye conditions. He is particularly known for his expertise in retinal diseases and for taking a thoughtful, evidence-based approach to care, helping patients and parents understand their diagnosis and treatment options clearly and calmly.
With a strong background in both clinical practice and medical research, Dr Teo combines advanced diagnostics with personalised care, ensuring each patient receives treatment that is appropriate, precise, and carefully considered.
Dr Teo manages a wide range of eye conditions, with a special focus on retinal diseases in both children and adults, including:
His subspecialty training allows him to manage complex and rare retinal conditions with a strong focus on long-term vision preservation, especially important for growing children.
Dr Teo completed his specialist training at the Singapore National Eye Centre (SNEC), where he practised for over a decade. He continues to contribute to paediatric and advanced eye care as a clinician and researcher, supporting children and adults with complex retinal conditions.
He is also actively involved in research and clinical innovation through his work with the Singapore Eye Research Institute (SERI), helping bring new and emerging treatments into clinical practice.
Dr Kelvin Teo graduated from Barts and The London School of Medicine and Dentistry (UK) and later obtained a PhD in Medical Research from the University of Sydney, Australia.
His advanced subspecialty training includes:
This dual fellowship training equips Dr Teo to manage both common and highly complex retinal conditions using evidence-based therapies.
Dr Teo is accredited to perform procedures at:
Dr Teo is a lead researcher at the Singapore Eye Research Institute (SERI) and has published over 100 peer-reviewed medical papers. His research focuses on retinal diseases, aging eye conditions, and novel therapies, including gene and complement-based treatments.
In 2024, Dr Teo administered Singapore’s first early-access anti-complement therapy for geographic atrophy, an advanced form of dry age-related macular degeneration.